Zacks Research Brokers Raise Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Zacks Research increased their Q1 2025 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($1.33) for the quarter, up from their previous forecast of ($1.77). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.40) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.24) EPS.

Several other equities analysts have also recently weighed in on the stock. Mizuho raised their target price on shares of Axsome Therapeutics from $195.00 to $212.00 and gave the company an “outperform” rating in a research note on Wednesday, February 26th. Bank of America raised their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Truist Financial raised their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Royal Bank of Canada raised their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $167.36.

Axsome Therapeutics Stock Performance

AXSM opened at $121.91 on Friday. The stock has a market capitalization of $5.94 billion, a price-to-earnings ratio of -20.35 and a beta of 1.00. The company has a fifty day moving average of $112.25 and a 200 day moving average of $98.82. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 22.40% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. Royce & Associates LP lifted its holdings in Axsome Therapeutics by 73.1% during the 3rd quarter. Royce & Associates LP now owns 22,500 shares of the company’s stock valued at $2,022,000 after buying an additional 9,500 shares in the last quarter. Whalen Wealth Management Inc. bought a new stake in Axsome Therapeutics during the 3rd quarter valued at about $236,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Axsome Therapeutics during the 3rd quarter valued at about $830,000. Moors & Cabot Inc. bought a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at about $200,000. Finally, Intech Investment Management LLC bought a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at about $983,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.